WO2001030966A3 - An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system - Google Patents

An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system Download PDF

Info

Publication number
WO2001030966A3
WO2001030966A3 PCT/US2000/029151 US0029151W WO0130966A3 WO 2001030966 A3 WO2001030966 A3 WO 2001030966A3 US 0029151 W US0029151 W US 0029151W WO 0130966 A3 WO0130966 A3 WO 0130966A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune system
effector functions
recombinant molecule
cellular effector
engineered recombinant
Prior art date
Application number
PCT/US2000/029151
Other languages
French (fr)
Other versions
WO2001030966A2 (en
Inventor
William L Fodor
Maryellen Pizzolato
Original Assignee
Alexion Pharma Inc
William L Fodor
Maryellen Pizzolato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, William L Fodor, Maryellen Pizzolato filed Critical Alexion Pharma Inc
Priority to EP00975335A priority Critical patent/EP1165752A4/en
Priority to CA002361646A priority patent/CA2361646A1/en
Priority to AU13401/01A priority patent/AU1340101A/en
Publication of WO2001030966A2 publication Critical patent/WO2001030966A2/en
Publication of WO2001030966A3 publication Critical patent/WO2001030966A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Recombinant chimeric molecules that include at least a domain capable of regulating the humoral effector functions of the immune system and another domain capable of regulating the cellular effector functions of the immune system are provided. Recombinant DNA constructs having DNA sequences encoding the above mentioned chimeric proteins are provided. Cloning vectors incorporating the above DNA constructs and cells transformed with the vectors and host cells containing such vectors are also provided. Transgenic cells, tissues, organs, and animals incorporating the above-mentioned chimeric molecules are provided.
PCT/US2000/029151 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system WO2001030966A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00975335A EP1165752A4 (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
CA002361646A CA2361646A1 (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
AU13401/01A AU1340101A (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16118699P 1999-10-22 1999-10-22
US60/161,186 1999-10-22

Publications (2)

Publication Number Publication Date
WO2001030966A2 WO2001030966A2 (en) 2001-05-03
WO2001030966A3 true WO2001030966A3 (en) 2001-10-18

Family

ID=22580195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029151 WO2001030966A2 (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Country Status (4)

Country Link
EP (1) EP1165752A4 (en)
AU (1) AU1340101A (en)
CA (1) CA2361646A1 (en)
WO (1) WO2001030966A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006292827B2 (en) 2005-08-09 2013-02-14 Revivicor, Inc. Transgenic ungulates expressing CTLA4-IG and uses thereof
ES2767881T3 (en) 2009-08-14 2020-06-18 Revivicor Inc Multi-transgenic pigs for the treatment of diabetes
CN106432474A (en) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 CTLA4 proteins and their uses
ES2680636T3 (en) 2011-02-14 2018-09-10 Revivicor Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
EP4247151A1 (en) 2020-11-20 2023-09-27 Revivicor Inc. Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation
IL311538A (en) 2021-09-20 2024-05-01 Revivicor Inc Multitransgenic pigs comprising ten genetic modifications for xenotransplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEW ET AL.: "Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions", VACCINE, vol. 18, no. 16, 25 February 2000 (2000-02-25), pages 1681 - 1685, XP002940996 *
NAKANO ET AL.: "Determination of the active site of CD59 with synthetic peptides", MOLECULAR IMMUNOLOGY, vol. 32, no. 4, March 1995 (1995-03-01), pages 241 - 247, XP002940997 *
See also references of EP1165752A4 *
ZHOU ET AL.: "Expression of recombinant CD59 with an N-terminal peptide epitope facilitates analysis of residues contributing to its complement-inhibitory function", MOLECULAR IMMUNOLGY, vol. 33, no. 14, October 1996 (1996-10-01), pages 1127 - 1134, XP002940998 *

Also Published As

Publication number Publication date
EP1165752A2 (en) 2002-01-02
AU1340101A (en) 2001-05-08
CA2361646A1 (en) 2001-05-03
WO2001030966A2 (en) 2001-05-03
EP1165752A4 (en) 2003-02-05

Similar Documents

Publication Publication Date Title
WO2003093296A3 (en) Kinase anchor protein muteins, peptides thereof, and related methods
EP1209237A3 (en) Synthetic DNA sequence having enhanced insecticidal activity in maize
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
AU7599500A (en) Novel gl50 molecules and uses therefor
WO2001038357A3 (en) Jaffa, a novel fibroblast growth factor family member and uses therefor
WO2002070538A3 (en) Narc8 programmed cell-death-associated molecules and uses thereof
WO2002000722A3 (en) Human calcium channels (48000; 52920) and uses thereof
WO2001030966A3 (en) An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
WO2002000718A3 (en) A human calcium channel protein and uses thereof
WO2000052164A3 (en) Potassium channel molecules and uses therefor
WO2002016591A3 (en) Human transporter family members and uses thereof
WO1997032022A3 (en) Canine ob protein compositions and methods
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
WO2002016589A3 (en) Human abc transporter family member and uses thereof
WO2001032872A3 (en) Twik potassium channel molecules and uses therefor
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
WO2000018923A3 (en) Slgp protein and nucleic acid molecule and uses therefor
AU2001253258A1 (en) Human trp-like calcium channel protein-2 (tlcc-2)
WO2002029042A3 (en) 48120, 23479, and 46689, novel human hydrolases and uses thereof
WO2002088357A3 (en) 84242, 8035, 55304, 52999, and 21999, novel human proteins and methods of use thereof
WO2001072828A3 (en) 26649, a human gtpase activating molecule and uses therefor
AU2002352068A1 (en) 2150, a human protein kinase family member and uses therefor
WO2001042286A3 (en) Human leucine rich repeat-containing polypeptide and uses therefor
AU2002359572A1 (en) 15603, a human ion channel family member
WO2002010401A3 (en) 18431 and 32374, human protein kinase family members and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2361646

Country of ref document: CA

Ref country code: CA

Ref document number: 2361646

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000975335

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000975335

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000975335

Country of ref document: EP